Axogen, Inc. (AXGN) News
Filter AXGN News Items
AXGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AXGN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AXGN News From Around the Web
Below are the latest news stories about AXOGEN INC that investors may wish to consider to help them evaluate AXGN as an investment opportunity.
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Craig Swandal, experienced medical device manufacturing executive, joins leadership teamALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Craig Swandal as Vice President of Operations. Mr. Swandal will report to Michael Dale, President, and Chief Executive Officer, and will be responsible for manufacturing, supply |
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2024 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth quarter of 2023 driven by sol |
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year. |
Those who invested in Axogen (NASDAQ:AXGN) a year ago are up 98%The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you... |
Are Medical Stocks Lagging Doximity (DOCS) This Year?Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year. |
All You Need to Know About AxoGen (AXGN) Rating Upgrade to BuyAxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18%The mean of analysts' price targets for AxoGen (AXGN) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Axogen Third Quarter 2024 Earnings: Beats ExpectationsAxogen ( NASDAQ:AXGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$48.6m (up 18% from 3Q 2023). Net... |
AxoGen Reports Strong Q3 2024 Revenue GrowthAxoGen ( (AXGN) ) just unveiled an update. Axogen, Inc., a leader in peripheral nerve repair solutions, reported a notable 17.9% revenue increase for Q3 2024 at $48.6 million, alongside a decrease in net loss to $1.9 million from $4.1 million in the previous year. The company’s strategic advancements include FDA acceptance of its Biologics License Application for Avance Nerve Graft and promising engagement at industry events. Axogen aims to hit the high end of its revenue and gross margin guidan |